Holding(s) in Company

RNS Number : 9634C
e-Therapeutics plc
15 March 2011
 



 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi



1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii


E-Therapeutics plc

 

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights:

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached:


An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments:


An event changing the breakdown of voting rights:


Other (please specify):



3. Full name of person(s) subject to the notification obligation: iii

RAB Capital plc acting as discretionary manager for RAB Special Situations (Master) Fund Ltd.

4. Full name of shareholder(s) (if different from 3.):iv

Credit Suisse Client Nominees (UK) Ltd

5. Date of the transaction and date on which the threshold is crossed or reached: v

04.03.11

6. Date on which issuer notified:

15.03.11

7. Threshold(s) that is/are crossed or reached: vi, vii

21%- 4%



 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

ORDINARY SHARES*

GB00B2823H99

16,357,950

16,357,950


n/a

4,557,950


3.3%


B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date
xiii

Exercise / Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting
rights






C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date xvii

Exercise/
Conversion period
xviii

Number of voting rights instrument refers to

% of voting rights xix, xx






Nominal

Delta


Total (A+B+C)

Number of voting rights

Percentage of voting rights

4,557,950

3.3%

 

 

 

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

 

*RAB Capital plc acts as investment manager for RAB Special Situations (Master) Fund Ltd who are the beneficial owner of the securities. The legal title to these securities is held on behalf of the beneficial owners by their nominee, Credit Suisse Client Nominees (UK) Ltd

Proxy Voting:

10. Name of the proxy holder:

n/a

11. Number of voting rights proxy holder will cease to hold:

n/a

12. Date on which proxy holder will cease to hold voting rights:

n/a

13. Additional information:

n/a

14. Contact name:

RAB Capital plc - Legal Team

15. Contact telephone number:

020 7389 7000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEAEDSFDDFEFF
UK 100

Latest directors dealings